New Company Formed for Development of new cardiac toxicity assays

San Diego, Calif., November 12, 2011 – Three entrepreneurs have joined to form a new company called TissueNetix, Inc., based in San Diego, CA.  The long-term goal of TissueNetix is to develop high-throughput assays based on human cellular networks.  The first assay that the company is targeting will detect compounds in the drug discovery process that have cardiac toxicity.  The founders are David Giegel, Ph.D., Roberta Gottlieb, M.D., and Lewis Shuster, M.B.A.

Read more: New Company Formed
Go to top